Dry Eye

According to the company, full enrollment anticipated by first week of September. The phase 2 trial is designed as potential registration trial with pre-specified primary efficacy endpoints covering both a sign and symptom of DED.

The organization says to stop using Dr. Berne’s and LightEyez MSM drops immediately due to bacterial contamination, fungal contamination, or both.

For clinicians, the evolution of treatment is as much a responsibility as an opportunity.

Treating the meibomian glands and lifestyle changes are among some of the treatment methods.

Lead author Sean Paul, MD, reports radiofrequency treatment in conjunction with expression of the meibomian glands reduces the signs and symptoms of dry eye disease.

Selina McGee, OD, FAAO, shares her comprehensive examination and treatment approach, underscoring the importance of tailoring treatments based on the individual's dry eye evaluation.

Selina McGee, OD, FAAO, presents a patient case referred for ocular surface optimization in preparation for cataract surgery.

John Sheppard, MD, explains the potential harm caused by over-the-counter artificial tears with preservatives on the ocular surface and discusses innovative ocular-sparing treatments that stimulate tear production.

John Sheppard, MD, reviews the case of a 63-year-old male with evaporative dry eye, facing challenges in managing his symptoms using over-the-counter artificial tears.

John Sheppard, MD, discusses the impact of continuous contact lens use on dry eye, often masking its signs, and explores treatment strategies for patients using contact lenses.

John Sheppard, MD, presents a dry eye case involving a 48-year-old female patient who has been using contact lenses for approximately three decades.

Treatment requires a systematic, multifaceted approach to improve outcomes.

Physicians ask the right questions and take an aggressive approach to treatment.

Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss their preferred clinical diagnostic tools and tests to evaluate patients for dry eye disease (DED) and strategies for educating patients on their results.

Experts offer their clinical perspectives on the use of dry eye questionnaires as a method of screening for dry eye disease (DED).

Experts discuss the impact of dry eye disease (DED) on coexisting ocular conditions and their clinical experience managing these patients.

Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss the prevalence of dry eye disease (DED) and how it can impact the quality of life for patients.

Influencers on TikTok claim the vegetable oil promotes eye health. However, ophthalmologists say the risks aren't worth any minimal benefits.

Cochair Peter J. McDonnell, MD, highlights what this year’s conference will mean for clinicians and addresses the anticipated increased patient volume.

According to the companies, the divested assets will include Xiidra and SAF312, a potential therapy for chronic ocular surface pain. The deal is expected to close later this year.

As part of its effort, the company is kicking off a new social media campaign in July designed to increase the understanding of dry eye disease.

Experts in the field weigh in on the perfluorohexyloctane ophthalmic solution, the first and only FDA-approved treatment for DED that directly targets tear evaporation instead of tear formation.

In a presentation at the American Society for Microbiology’s annual meeting, the oral administration of a commercially available probiotic bacterial strain was found to improve dry eye disease in an animal model.

AG-80208 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop to treat the inflammation linked with DED.

The agreement includes rights to develop, manufacture and commercialize NOV03 in Japan for the treatment of dry eye disease.

RAFARM and BioNanoSim have entered into an agreement to create the company.

According to the company, CyclASol is preservative-free and does not contain any oils or surfactants, which can be irritating and disturbing for the tear film.

The topical drug is being tested in a multi-center, double-masked, placebo-controlled trial to treat dry eye disease (DED).